Healthcare provider profile · identity verified

Everett Hsu, MD

Internal Medicine · OAKLAND, CA · NPI 1215015086

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	457	161
Amlodipine Besylate	Amlodipine Besylate	311	113
Hydrochlorothiazide	Hydrochlorothiazide	281	107
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	184	35
Losartan Potassium	Losartan Potassium	184	62
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	176	62
Lisinopril	Lisinopril	158	55
Levothyroxine Sodium	Levothyroxine Sodium	151	49
Gabapentin	Gabapentin	140	49
Fluticasone Propionate	Fluticasone Propionate	105	38
Albuterol Sulfate Hfa	Albuterol Sulfate	103	49
Lovastatin	Lovastatin	92	30
Metformin Hcl Er	Metformin Hcl	87	34
Atenolol	Atenolol	86	32
Tamsulosin Hcl	Tamsulosin Hcl	85	34
Alendronate Sodium	Alendronate Sodium	81	30
Metoprolol Tartrate	Metoprolol Tartrate	77	29
Simvastatin	Simvastatin	74	24
Oxycodone Hcl	Oxycodone Hcl	73	11
Paxlovid	Nirmatrelvir/Ritonavir	72	72
Trazodone Hcl	Trazodone Hcl	69	23
Terazosin Hcl	Terazosin Hcl	68	21
Allopurinol	Allopurinol	67	24
Metoprolol Succinate	Metoprolol Succinate	50	14
Metformin Hcl	Metformin Hcl	45	16
Alvesco	Ciclesonide	44	17
Colchicine	Colchicine	44	20
Famotidine	Famotidine	44	16
Pradaxa	Dabigatran Etexilate Mesylate	44	18
Omeprazole	Omeprazole	42	16
Fluocinonide	Fluocinonide	41	23
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	37	37
Triamcinolone Acetonide	Triamcinolone Acetonide	36	25
Baclofen	Baclofen	35	12
Spiriva Respimat	Tiotropium Bromide	35	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	33	suppressed
Furosemide	Furosemide	31	15
Temazepam	Temazepam	30	suppressed
Ibuprofen	Ibuprofen	28	17
Finasteride	Finasteride	27	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	27	suppressed
Nabumetone	Nabumetone	27	21
Sertraline Hcl	Sertraline Hcl	27	suppressed
Sulindac	Sulindac	27	12
Amitriptyline Hcl	Amitriptyline Hcl	26	suppressed
Breyna	Budesonide/Formoterol Fumarate	25	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	12
Spironolactone	Spironolactone	22	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Morphine Sulfate Er	Morphine Sulfate	20	suppressed
Naproxen	Naproxen	20	suppressed
Topiramate	Topiramate	20	suppressed
Lorazepam	Lorazepam	19	12
Montelukast Sodium	Montelukast Sodium	19	suppressed
Carvedilol	Carvedilol	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Potassium Chloride	Potassium Chloride	18	suppressed
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Prednisone	Prednisone	18	12
Acyclovir	Acyclovir	17	suppressed
Hydrocortisone	Hydrocortisone	17	12
Pantoprazole Sodium	Pantoprazole Sodium	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Diazepam	Diazepam	16	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	16	14
Ondansetron Odt	Ondansetron	16	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	16	suppressed
Glipizide Er	Glipizide	15	suppressed
Jardiance	Empagliflozin	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Celecoxib	Celecoxib	14	suppressed
Morphine Sulfate	Morphine Sulfate	14	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Cefadroxil	Cefadroxil	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Trospium Chloride	Trospium Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error